Mechanisms of statin-induced myopathy: A role for the ubiquitin-proteasome pathway?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 12, 2005, Pages 2441-2444

  Chapman, M John ^a,b   Carrie, Alain ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CALMODULIN; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESSENGER RNA; PRAVASTATIN; PROTEASOME; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; DRUG INDUCED DISEASE; EDITORIAL; GENE EXPRESSION; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MYALGIA; MYOPATHY; MYOSITIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RHABDOMYOLYSIS; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; INCIDENCE; METABOLISM; NOTE; RISK FACTOR;

CARDIOMYOPATHIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; PROTEASOME ENDOPEPTIDASE COMPLEX; RISK FACTORS; UBIQUITIN;

EID: 33644790562     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/10.1161/01.ATV.0000194548.11901.a4     Document Type: Editorial

References (19)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278.
2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. For the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
3. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
4. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN. For the REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc. 2004;291:1071-1080.
5. Ray KK, Cannon CP. Early tissue to benefit with intensive statin treatment: could it be the pleiotropic effects ? Am J Cardiol 2005;96:54F-60F
6. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
7. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C; American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567-572.
8. Ucar M, Mjorndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Safety. 2000;22:441-457.
9. Tobert JA. Lovastatin and beyond: the history of HMGCoA Reductase inhibitors. Nature Reviews Drug Discovery. 2005;4:45-55.
10. Urso ML, Clarkson PM, Hittel D, Hoffman EP, Thompson PD. Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol. 2005;25;2560-2566.
11. Willoughby DS, Taylor M, Taylor L. Glucocorticoid receptor and ubiquitin expression after repeated eccentric exercice. Med Sci Sports Exerc. 2003;35:2023-2031.
12. Jones SW, Hill RJ, Krasney PA, O'Conner B, Peirce N, Greenhaff PL. Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. FASEB J. 2004;18(9):1025-7.
13. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiological Reviews. 2002;82:373-428.
14. Varshavsky A. Regulated protein degradation. Trends Biochem Sci. 2005;30:283-286.
15. Mason RP, Walter MF, Day CA, Jacob RF. Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol. 2005;96(5A):11F-23F
16. Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, Laasko J, Lehtimaki T, Von Bergmann K., Lutjohann D, Laaksonen R. High dose statins and skeletal muscle metabolism in humans : a randomized, controlled trial. Clin Pharmacol Ther. 2005;78:60-68.
17. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, Vladutiu GD, England JD. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581-585.
18. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E; A to Z Investigators. Early intensive vs a delayed conservative Simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z Trial. JAMA. 2004;292:1307-1316.
19. Waters DD. Safety of high-dose Atorvastatin therapy. Am J Cardiol. 2005;96:69F-75F